GlassScriptPhysician profile
Kastle Donovan
NPI 1174811897
$1,321.89
in general payments reported to CMS, 2019-2025
18 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.77 · 2023: $450 · 2024: $719 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.67 | 2023-2024 | |
| Novo Nordisk INC | $157.32 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $108.94 | 2023 | |
| Medtronic, INC. | $104.27 | 2025 | Symplicity G3 |
| Astellas Pharma US INC | $93.96 | 2024 | Veozah |
| Lilly USA, LLC | $79.71 | 2022-2024 | Jardiance, Emgality |
| Axsome Therapeutics, INC. | $62.62 | 2023-2024 | Auvelity |
| Merz North America, INC. | $31.57 | 2022 | |
| Nevro Corp. | $30.36 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.75 | 2024 | Jardiance |
| Gilead Sciences, INC. | $25.08 | 2024 | |
| Neos Therapeutics, LP | $23.38 | 2023 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $22.57 | 2023 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $21.38 | 2024 | Quviviq |
| Amgen INC. | $21.20 | 2024 | Evenity, Prolia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $20.02 | 2024 | Fluad, Flucelvax |
| Astrazeneca Pharmaceuticals LP | $19.95 | 2023 | Farxiga |
| Phathom Pharmaceuticals, INC. | $15.14 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kastle Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.